Skip to main content
logo
Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
10.57
+0.32 (3.12%)
Nov 6, 2026, 4:00 PM EST - Market closed

Monte Rosa Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
70.33123.6775.62---
Revenue Growth
-61.26%63.54%----
Gross Profit
-63.38-10.03-37.24-103.37--
Operating Income
-150.82-54.21-81.11-143.31-112.38-72.88
Net Income
-130.97-38.63-72.7-135.35-108.5-73.96
Earnings Per Share
-1.35-0.46-0.98-2.63-2.30-2.96
EPS Growth
------

Cash & Debt
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
577.73377.1372.15232.41262.83346.07
Total Debt
36.2739.1942.7246.0447-
Net Cash (Debt)
541.46337.91329.43186.37215.83346.07
Net Cash Growth
54.22%2.57%76.76%-13.65%-37.64%729.93%
Net Cash Per Share
5.574.074.463.634.5713.84

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-165.48-22.842-43.8-92.47-59.36
Capital Expenditures
-8.92-4.7-3.99-19.04-12.91-9.73
Free Cash Flow
-174.39-27.538.01-62.84-105.38-69.1
Free Cash Flow Growth
------

Margins
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-90.12%-8.11%-49.25%---
Operating Margin
-214.46%-43.83%-107.26%---
Pretax Margin
-184.77%-32.12%-92.74%---
Profit Margin
-186.24%-31.23%-96.14%---
FCF Margin
-247.98%-22.23%50.26%---

Valuation
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
P/FCF Ratio
--11.22---
PS Ratio
12.828.265.64---